ClinicalTrials.gg
CompletedNCT02398513Updated Aug 1, 2016

Regorafenib Phase I Study in Mainland Chinese Patients

A Phase 1 interventional study of Regorafenib (Stivarga, BAY73-4506) in Oncology, sponsored by Bayer. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-01.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.

The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib

02

Conditions studied

  • Oncology

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed (IC) obtained before any study specific procedure. Patients must be able to understand and be willing to sign the written informed consent
  • Patients with or cytologically confirmed,,locally advanced or solid tumors who are not candidates for standard therapy or in whom the specific clinical indications for which Regorafenib is approved elsewhere in the world is considered an appropriate treatment option.
  • Male or female Chinese patients living in China mainland >= 18 years
  • Patients must have measurable or non- according to , version 1.1
  • performance status (ECOG-PS 0 - 1)
  • (BMI) between 18 and 33 kg/m2 inclusive
  • Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:

    • count >= 100,000/cubic millimeters (mm3), (Hb) >= 9 g/dl, leukocyte count > 3,000/mm3, (ANC) >=1,500/mm3. Transfusion to meet the inclusion criteria will not be allowed.
    • Total \<= 1.5 x the (ULN).
    • (ALT) and aspartate aminotransferase (AST) \<= 3.0 x ULN (\<= 5 x ULN for patients with liver involvement of their cancer)
    • Alkaline phosphatase limit \<= 2.5 x ULN (\<= 5 x ULN for patients whose cancer involves their liver and/or bone)
    • Lipase \<= 1.5 x ULN
    • Serum creatinine \<= 1.5 times ULN and estimated (CLcr) >= 30 mL/min according to the Cockroft-Gault formula
  • (INR) \<= 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) \<= 1.5 x ULN. Patients being treated with anticoagulant, e.g. warfarin or heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care.
  • of at least 3 months.
  • Women of must have a pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with Regorafenib
  • Patients unable to swallow and retain oral medications
  • Any other malignant disease treated \< 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1)
  • Symptomatic brain or meningeal tumors if the patient is \< 6 months from definitive therapy, has evidence of tumor growth on an imaging study within 4 weeks prior to study entry and is on dexamethasone and not clinically stable with respect to the tumor at the time of study entry.
  • Major surgical procedure, or significant traumatic injury within 28 days before start of study medication
  • History of organ allograft
  • Non-healing wound, ulcer, or bone fracture
  • Uncontrolled hypertension (systolic blood pressure >150 millimeter of mercury (mmHg) or diastolic blood pressure >90 mmHg despite optimal medical management)
  • Persistent proteinuria > 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (>=Grade 3, v 4.03).
  • History of cardiac disease: congestive heart failure (CHF) >= (New York Heart Association) Class II. Active coronary artery disease unstable angina (angina symptoms at rest) or new-onset angina (within last 3 months) or myocardial infarction (MI) within past 6 months
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Regorafenib (Stivarga, BAY73-4506)

    Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.

    Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (maximum drug concentration in plasma)

    Time frame: Cycle 0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours

  2. AUC(0-24) (AUC from time 0 h to time 24 h post-administration)

    Time frame: Cycle 0 day1, 0、0.5、1、2、3、4、6、8、12、24 hours

  3. AUC(0-tlast) (AUC from time zero to the last data point>LLOQ)

    Time frame: Cycle0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours

  4. Cmax.ss (Cmax at steady-state during a dosage interval)

    Time frame: Cycle 1 day 21, 0,0.5,1,2,3,4,6,8,12,24,36,48,72,96 hours

  5. AUCt.ss (AUC for the dosing interval at steady-state)

    Time frame: cycle 1 day 21 0,0.5,1,2,3,4,6,8,12,24 hours

Secondary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 30 days

  2. Tumor Response base don RECIST 1.1 criteria

    Time frame: Up to 30 days

07

Study locations

1 site
  • Shanghai, 200032, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Nov 2015 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2015
First posted
Mar 25, 2015
Start
Apr 2015
Primary completionActual
Nov 2015
CompletionActual
Jun 2016
Last update
Aug 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02398513
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 25, 2015
Start date
Apr 2015
Primary completion
Nov 2015
Completion
Jun 2016
Last update
Aug 1, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion